Bloomberg's Tom Keene, Jonathan Ferro and Lisa Abramowicz break down the Federal Reserve's latest policy decision on a special edition of Bloomberg Surveillance

Bloomberg's Tom Keene, Jonathan Ferro and Lisa Abramowicz break down the Federal Reserve's latest policy decision on a special edition of Bloomberg Surveillance

Listen for reporting from the magazine that helps global leaders stay ahead. 

Hosts Carol Massar and Tim Stenovec bring you insight on the people, companies and trends shaping today's complex economy.  You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: http://bit.ly/3vTiACF. 

Listen for reporting from the magazine that helps global leaders stay ahead. Hosts Carol Massar and Tim Stenovec bring you insight on the people, companies and trends shaping today's complex economy.&nbsp; You can watch and listen to Businessweek LIVE on YouTube, weekdays from 2PM to 5PM ET: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.&nbsp;

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

Instant Reaction: The Fed Decides

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/8a166342-d893-44fb-830f-b24a0148476f/transcript

Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity.

Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Vir Biotechnology Vir is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. The company on Monday announced new data from the ongoing Phase 1 clinical trial of VIR-5500, a prostate-specific membrane antigen (PSMA)-targeting, PRO-XTEN dual-masked T-cell engager (TCE) being evaluated in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have progressed after multiple lines of therapy. These data suggest that VIR-5500 monotherapy is well tolerated and exhibits promising anti-tumor activity. Marianne De Backer, Ph.D., the CEO at Vir Bio, discusses the progress being made with the firm's leading treatments, the runup in its share price thus far in 2026, and why partnerships are key to advancing Vir's impact. Dr. De Backer speaks with Carol Massar and Tim Stenovec on Bloomberg Businessweek Daily.

Vir Bio's Cancer Treatment Progress Driving Shares Hight 

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/98a32413-f1fb-44b1-803a-b3fe016dbcbb/transcript

'Bloomberg This Weekend' features unique conversations on business, news, lifestyle and culture. Join David Gura, Christina Ruffini and Lisa Mateo Saturdays and Sundays for discussions with business leaders, lawmakers and cultural icons.  

Watch the show LIVE on Bloomberg Television from 7AM-10AM Eastern Time.   
Listen to the show LIVE on Bloomberg Radio from 7AM-10AM Eastern Time.   

Listen to the Podcast for the best conversations from the show.   
Subscribe on Apple: 
https://podcasts.apple.com/us/podcast/bloomberg-this-weekend/id1878739308
Subscribe on Spotify: 
https://open.spotify.com/show/5DQ8CEg9LeS1xGJSaxt47l

'Bloomberg This Weekend' features unique conversations on business, news, lifestyle and culture. Join David Gura, Christina Ruffini and Lisa Mateo Saturdays and Sundays for discussions with business leaders, lawmakers and cultural icons.&nbsp;&nbsp; Watch the show <a href="https://www.bloomberg.com/live">LIVE on Bloomberg Television</a> from 7AM-10AM Eastern Time.&nbsp; &nbsp; Listen to the show <a href="https://www.bloomberg.com/audio">LIVE on Bloomberg Radio</a> from 7AM-10AM Eastern Time.&nbsp; &nbsp; Listen to the Podcast for the best conversations from the show.&nbsp; &nbsp; Subscribe on Apple: <a href="https://podcasts.apple.com/us/podcast/bloomberg-this-weekend/id1878739308">https://podcasts.apple.com/us/podcast/bloomberg-this-weekend/id1878739308</a> Subscribe on Spotify: <a href="https://open.spotify.com/show/5DQ8CEg9LeS1xGJSaxt47l">https://open.spotify.com/show/5DQ8CEg9LeS1xGJSaxt47l</a>

Introducing: Bloomberg This Weekend

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/1d31f324-03ff-4d5a-97ae-b3fb00b2aa0a/transcript

The US and Israel began striking targets across Iran, with President Donald Trump urging Iranians to overthrow the government in a conflict that threatens to spiral across the oil-rich Middle East.   

“The hour for your freedom is at hand,” Trump said, addressing Iranians in a video posted on Truth Social on Saturday. “When we’re finished, take over your government. It will be yours to take. This will be probably your only chance for generations.”   

The military campaign could be a defining moment for Trump, risking a drawn-out regional war that leads to a surge in energy prices and American casualties ahead of mid-term elections this year. Iran quickly responded by firing missiles on Israel and US bases around the region, and countries in the Persian Gulf closed their airspace.  

Israel’s military said the campaign would target “dozens of military targets,” and Iran media reported strikes on defensive and civilian sites, including more than 50 people dead in a strike on a school in Hormozgan, in the south of the country. Several large explosions were reported in the capital, Tehran.   
Bloomberg's David Gura and Christina Ruffini lead our team coverage in this instant reaction podcast.

The US and Israel began striking targets across Iran, with President Donald Trump urging Iranians to overthrow the government in a conflict that threatens to spiral across the oil-rich Middle East.&nbsp; &nbsp; &ldquo;The hour for your freedom is at hand,&rdquo; Trump said, addressing Iranians in a video posted on Truth Social on Saturday. &ldquo;When we&rsquo;re finished, take over your government. It will be yours to take. This will be probably your only chance for generations.&rdquo;&nbsp; &nbsp; The military campaign could be a defining moment for Trump, risking a drawn-out regional war that leads to a surge in energy prices and American casualties ahead of mid-term elections this year. Iran quickly responded by firing missiles on Israel and US bases around the region, and countries in the Persian Gulf closed their airspace.&nbsp;&nbsp; Israel&rsquo;s military said the campaign would target &ldquo;dozens of military targets,&rdquo; and Iran media reported strikes on defensive and civilian sites, including more than 50 people dead in a strike on a school in Hormozgan, in the south of the country. Several large explosions were reported in the capital, Tehran.&nbsp; &nbsp; Bloomberg's David Gura and Christina Ruffini lead our team coverage in this instant reaction podcast.

Instant Reaction: US, Israel Attack Iran as Trump Urges Regime Change

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/450f6ecf-5bac-4013-adee-b3ff00e34d43/transcript

Instant Reaction: The Fed Decides

In 1 playlist(s)

Bloomberg Businessweek

Social links

Follow podcast

Recent clips